Companies Dominating the Controlled Substance API Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson & Johnson
- Novartis AG
- Roche Holding AG
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Eli Lilly and Company
- AstraZeneca plc
- Merck & Co., Inc.
- AbbVie Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of controlled substance API is assessed at USD 13.78 billion.
The controlled substance API market size was valued at USD 11.94 billion in 2024 and is expected to reach USD 37.94 billion by 2037, expanding at around 9.3% CAGR during the forecast period i.e., between 2025-2037. Increasing investment in pharmaceutical infrastructure will drive the market growth.
Asia Pacific industry is predicted to dominate majority revenue share of 40% by 2037, as countries in the region are progressively updating their regulatory frameworks to ensure the safety, quality, and efficacy of pharmaceutical products.
The major players in the market are Pfizer Inc., Johnson & Johnson, Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., AbbVie Inc.
